SCHEMBL27211151

SCHEMBL27211151

COc1ncc(C2CCCN(C(=O)OC(C)(C)C)C2)cc1N

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.47
PRMT5 O14744 1/20 0.47
HPGDS O60760 2/20 0.45
ALOX5AP P20292 2/20 0.45
FEN1 P39748 2/20 0.45
PIK3CA P42336 3/20 0.42
JAK2 O60674 1/20 0.42
JAK1 P23458 1/20 0.42
RIPK1 Q13546 1/20 0.42
PIK3CD O00329 3/20 0.42
BACE1 P56817 2/20 0.40
CTSD P07339 1/20 0.40
PROKR1 Q8TCW9 1/20 0.40
GPR119 Q8TDV5 1/20 0.40
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25343649 1.00 PDE4B (0.47) PDE4BPRMT5HPGDSALOX5APFEN1
SCHEMBL27211356 0.88 PIK3CD (0.51) PDE4BPRMT5HPGDSALOX5APFEN1
SCHEMBL30473674 0.88 PIK3CD (0.51) PDE4BPRMT5HPGDSALOX5APFEN1
SCHEMBL25344277 0.88 PIK3CD (0.51) PDE4BPRMT5HPGDSALOX5APFEN1
SCHEMBL25342400 0.87 PDE4B (0.47) PDE4BPRMT5HPGDSALOX5APFEN1
SCHEMBL29457556 0.87 PDE4B (0.47) PDE4BPRMT5HPGDSALOX5APFEN1
SCHEMBL27211334 0.87 PDE4B (0.47) PDE4BPRMT5HPGDSALOX5APFEN1
SCHEMBL25343640 0.87 PDE4B (0.47) PDE4BPRMT5HPGDSALOX5APFEN1
SCHEMBL27211190 0.87 PDE4B (0.47) PDE4BPRMT5HPGDSALOX5APFEN1
SCHEMBL30473704 0.86 PRMT5 (0.46) PDE4BPRMT5HPGDSALOX5APFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11976057-B2 MrgX2 antagonists GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-05-07 US disclosed
CN-116390917-A MRGX2 antagonists 葛兰素史密斯克莱知识产权发展有限公司 2023-07-04 CN disclosed
US-20220112174-A1 MRGX2 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11976057-B2 MrgX2 antagonists MRGPRX2, MRGPRX1, MRGPRX4 PDE4B 1768/4885PRMT5 907/4885HPGDS 208/4885
US-20220112174-A1 MRGX2 ANTAGONISTS MRGPRX2, MRGPRX1, MRGPRX4 PDE4B 1768/4885PRMT5 907/4885HPGDS 208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.